Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
CONATUS PHARMACEUTICALS INC
Jurisdiction of Incorporation/Organization
DE
Year of Incorporation/Organization
Over Five Years Ago
Item 2 Issuer Principal Place of Business and Contact Information
4365 EXECUTIVE DRIVE
SUITE 200
SAN DIEGO, CA 92121
Phone Number:
subscription required
Item 3. Related Persons
Name
STEVEN J. MENTO
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
WILLIAM GERBER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
DAVID F. HALE
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
PAUL KLINGENSTEIN
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
SHAHZAD MALIK
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
MARC PERET
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
HAROLD VAN WART
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ALFRED P. SPADA
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
CHARLES J. CASHION
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JENNIFER GIOTTONINI CAYER
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
BIOTECHNOLOGY
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
03/05/2010
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
- Debt
- Option, Warrant or Other Right to Acquire Another Security
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
5000000
Total Amount Sold
5000000
Total Remaining to be Sold
0
Clarification of Response
TOTAL OFFERING AMOUNT AND TOTAL AMOUNT SOLD IS THE SUM OF THE FIRST CLOSING AND SECOND CLOSING WHICH OCCURRED ON MARCH 5, 2010 AND OCTOBER 15, 2010, RESPECTIVELY.
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
15
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
CONATUS PHARMACEUTICALS INC
Issuer Signature
/S/ CHARLES J. CASHION
Signer Name
CHARLES J. CASHION
Signer Title
SVP FINANCE, CFO AND SECRETARY
Signature Date
10/28/2010